OFA
VTGN icon

Oak Family Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Oak Family Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,025
Closed -$344K – 136
2022
Q2 		$344K Buy
13,025
+6,301
+94% +$222K 0.17% 88
2022
Q1 		$250K Buy
6,724
+573
+9% +$25K 0.1% 120
2021
Q4 		$360K Buy
6,151
+277
+5% +$18K 0.13% 103
2021
Q3 		$483K Buy
5,874
+222
+4% +$19.3K 0.18% 78
2021
Q2 		$534K Buy
5,652
+3,320
+142% +$246K 0.22% 61
2021
Q1 		$149K Sell
2,332
-465
-17% -$31K 0.06% 88
2020
Q4 		$163K Buy
+2,797
New +$71.4K 0.08% 95

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oak Family Advisors's VTGN Position: Q3 2022 in Review

Oak Family Advisors sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 13,025 shares — an estimated $344K sold.

Oak Family Advisors first reported a position in VTGN in Q4 2020 and held it in 7 quarters. The position peaked at $534K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Oak Family Advisors reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Oak Family Advisors sold 13,025 VistaGen Therapeutics shares in Q3 2022, an estimated $344K.
  • Oak Family Advisors first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 7 quarters.
  • Oak Family Advisors's VistaGen Therapeutics position peaked at $534K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Oak Family Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.